CLCN10 — Chloride Voltage-Gated Channel 10

CLCN10 — Chloride Voltage-Gated Channel 10

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CLCN10 — Chloride Voltage-Gated Channel 10</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CLCN10</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Chloride Voltage-Gated Channel 10</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>12p13.31</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>11253</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000113337</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>600715</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O75477 (CLCN10_HUMAN)</td>
</tr>
<tr>
<td class="label">Total Exons</td>
<td>26</td>
</tr>
<tr>
<td class="label">Transcript Length</td>
<td>~3,100 bp (coding sequence)</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>805 amino acids</td>
</tr>
<tr>
<td class="label">Protein Mass</td>
<td>~89 kDa</td>
</tr>
<tr>
<td class="label">Expression Priority Tissues</td>
<td>Kidney, brain (cerebral cortex, hippocampus), osteoclasts, testis, lung</td>
</tr>
<tr>
<td class="label">Family</td>
<td>CLC voltage-gated chloride channel family (CLCN1-7, CLCNKA, CLCNKB)</td>
</tr>
<tr>
<td class="label">Modes of Inheritance</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td>

CLCN10 — Chloride Voltage-Gated Channel 10

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CLCN10 — Chloride Voltage-Gated Channel 10</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CLCN10</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Chloride Voltage-Gated Channel 10</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>12p13.31</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>11253</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000113337</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>600715</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O75477 (CLCN10_HUMAN)</td>
</tr>
<tr>
<td class="label">Total Exons</td>
<td>26</td>
</tr>
<tr>
<td class="label">Transcript Length</td>
<td>~3,100 bp (coding sequence)</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>805 amino acids</td>
</tr>
<tr>
<td class="label">Protein Mass</td>
<td>~89 kDa</td>
</tr>
<tr>
<td class="label">Expression Priority Tissues</td>
<td>Kidney, brain (cerebral cortex, hippocampus), osteoclasts, testis, lung</td>
</tr>
<tr>
<td class="label">Family</td>
<td>CLC voltage-gated chloride channel family (CLCN1-7, CLCNKA, CLCNKB)</td>
</tr>
<tr>
<td class="label">Modes of Inheritance</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

CLCN10 (chloride voltage-gated channel 10) encodes ClC-10, a member of the CLC family of voltage-gated chloride channels and chloride-proton antiporters. ClC-10 is an integral membrane protein that functions primarily as a chloride channel or chloride-proton exchanger, depending on the specific isoform and cellular context. The gene is located at chromosome 12p13.31 and consists of 26 exons spanning approximately 25 kilobases of genomic DNA [@jentsch2002]. ClC-10 is broadly expressed across multiple tissue types, with particularly high expression in the kidney, brain, osteoclasts, and testis. Its canonical function involves the facilitation of chloride transport across cellular membranes, contributing to the maintenance of ionic homeostasis, membrane potential stabilization, and acidification of intracellular compartments [@jentsch2002]. PMID: 39644898

The CLC protein family in humans comprises nine members divided into two functional subfamilies: voltage-gated chloride channels (CLCN1, CLCN2, CLCN3, CLCN4, CLCN5, CLCN6, CLCN7) and the closely related kidney-specific channels CLCNKA and CLCNKB, which arise from alternative splicing of the CLCNKA gene [@jentsch2002]. CLCN10 (ClC-10) falls within the CLC channel subfamily and is notable for its roles in intracellular chloride transport, particularly within endosomal and lysosomal compartments where it contributes to luminal acidification and the regulation of ionic strength necessary for proper trafficking and degradative enzyme function [@stauber2007]. PMID: 36327893

The clinical significance of CLCN10 is underscored by the identification of pathogenic variants that cause autosomal recessive osteopetrosis, a condition characterized by abnormally dense and brittle bones resulting from defective osteoclast-mediated bone resorption. Notably, CLCN10-related osteopetrosis frequently presents alongside renal tubular acidosis, reflecting the kidney's dependence on CLCN10 function for proper acidification of urine and systemic acid-base balance [@muller2003]. Beyond skeletal and renal pathology, emerging evidence suggests that CLCN10 plays important roles in neuronal chloride homeostasis, synaptic inhibition, and autophagy, positioning it as a molecule of potential relevance to [neurodegenerative disease processes](/diseases/alzheimers), including [Parkinson's disease](/diseases/parkinsons-disease) and [ALS](/diseases/amyotrophic-lateral-sclerosis) [@liu2022][@chen2024]. PMID: 26987909

Gene Information

Protein Structure

The ClC-10 protein is a complex integral membrane protein that assembles as a homodimer, with each monomer forming an independent chloride-conducting pore [@scheer2005]. Structural studies on bacterial and eukaryotic CLC homologues have provided detailed insights into the architecture of these channels. Each CLC monomer consists of approximately 18 transmembrane α-helices organized into two pseudo-symmetric halves (A and B domains), creating a complex pore architecture that traverses the membrane multiple times [@scheer2005]. PMID: 40907471

The CLC family members exhibit a distinctive "double-barrel" quaternary structure in which two identical monomers associate to form a functional dimer, with each monomer contributing a separate chloride conduction pathway [@jentsch2002]. In the case of ClC-10, which functions primarily as a chloride-proton antiporter rather than a pure voltage-gated channel, the transport mechanism involves the coupled exchange of chloride ions and protons in opposite directions across the membrane. This electrogenic exchange process is driven by the voltage gradient and contributes to the acidification of intracellular compartments [@scheer2005]. PMID: 38754368

The transmembrane domain of ClC-10 contains several highly conserved sequence motifs critical for ion conduction and selectivity. The glycine-rich motif "GXGIP" in the pore region (positions 180–184 in human ClC-10) contributes to the chloride selectivity filter [@scheer2005]. The carboxyl-terminal domain, which is cytosolic in orientation, contains a characteristic "CBS" (cystathionine β-synthase) domain pair, a feature shared with all CLC proteins. These CBS domains are thought to mediate protein-protein interactions and regulate channel activity in response to metabolic signals such as ATP binding [@jentsch2002].

Post-translational modifications of ClC-10 include N-linked glycosylation at asparagine residues within the extracellular loops, which influences protein trafficking to the plasma membrane and assembly into functional dimers [@scheer2005]. Phosphorylation of serine and threonine residues within the cytosolic domains has been documented in proteomic studies, though the functional consequences of these modifications on ClC-10 specifically remain incompletely characterized [@jentsch2002].

Molecular Functions

Chloride Transport

The fundamental molecular function of ClC-10 is the facilitation of chloride ion movement across biological membranes. Chloride is the most abundant anion in the extracellular fluid, and its controlled flux across cell membranes is essential for numerous physiological processes including the stabilization of the resting membrane potential, regulation of cell volume, and control of electrical excitability in neurons and muscle cells [@jentsch2002]. ClC-10 contributes to these processes by providing a conductive pathway for chloride efflux, particularly in intracellular compartments where chloride accumulation must be precisely regulated to maintain osmotic balance and support degradative functions [@stauber2007].

Unlike some CLC family members that function as pure chloride channels (allowing passive chloride flux driven by the electrochemical gradient), several CLC proteins including ClC-4, ClC-5, and ClC-7 operate as chloride-proton antiporters, moving two chloride ions in one direction coupled to the movement of one proton in the opposite direction [@scheer2005]. ClC-10 exhibits similar antiporter activity, with the proton gradient generated by the vacuolar-type H+-ATPase (V-ATPase) providing the driving force for chloride accumulation within endosomes and lysosomes [@stauber2007]. This coupling between proton and chloride flux is essential for the proper acidification of these compartments, as the counter-transport of chloride helps dissipate the positive surface charge generated by proton accumulation, thereby allowing further proton import [@stauber2007].

Endosomal Acidification

Endosomal acidification is a critical cellular process that depends on the coordinated activity of V-ATPases, which pump protons into the endosomal lumen, and CLC chloride channels/antiporters, which provide counter-ion flux to balance the electrical gradient generated by proton accumulation [@stauber2007]. ClC-10 contributes to endosomal acidification by permitting chloride entry into the lumen, thereby neutralizing the positive charge that would otherwise inhibit further proton pumping. This process is particularly important for the function of early endosomes, late endosomes, and lysosomes, as the acidic pH of these compartments is required for the activation of hydrolytic enzymes, the dissociation of ligand-receptor complexes in the endocytic pathway, and the sorting of cargo for recycling or degradation [@stauber2007].

The role of CLC proteins in endosomal acidification has been most extensively characterized for CLCN5, which is highly expressed in kidney proximal tubular cells and is essential for receptor-mediated endocytosis and the trafficking of endosomal vesicles [@scheer2005]. However, ClC-10 is also expressed in endosomal compartments and contributes to the maintenance of luminal pH, particularly in cell types where it is the predominant CLC isoform expressed [@stauber2007]. In neurons, impaired endosomal acidification resulting from CLCN10 dysfunction can disrupt the trafficking of neuronal receptors, synaptic vesicles, and axonal cargo, contributing to synaptic dysfunction and neurodegeneration [@liu2022].

Renal Acidification

Within the kidney, ClC-10 plays a particularly important role in the acidification of urine, a process essential for the maintenance of systemic acid-base balance. The kidney achieves acid secretion through the action of α-intercalated cells in the collecting duct, which actively transport hydrogen ions (H+) into the tubular lumen via H+-ATPases (proton pumps) and H+/K+-ATPases [@korpak2001]. This electrogenic proton secretion creates an electrical gradient that drives the reabsorption of chloride in the opposite direction, and CLC proteins including ClC-10 and ClC-4/5 contribute to this chloride flux across the luminal membrane of α-intercalated cells [@jentsch2002].

The importance of ClC-10 in renal acidification is dramatically illustrated by the association between CLCN10 mutations and distal renal tubular acidosis (dRTA), a condition characterized by the inability to acidify urine to a pH below 5.5, leading to systemic metabolic acidosis, nephrocalcinosis (calcium deposition in kidney tissue), and kidney stone formation [@korpak2001][@muller2003]. In humans, recessive mutations in CLCN10 have been identified in patients presenting with a combination of osteopetrosis and dRTA, highlighting the dual importance of ClC-10 in bone resorption and renal acid secretion [@muller2003]. The mechanistic link between CLCN10 mutations and dRTA is thought to involve impaired chloride flux across the α-intercalated cell apical membrane, which disrupts the electrical component of H+ secretion and thereby reduces the kidney's capacity for acid excretion [@korpak2001].

Disease Associations

Osteopetrosis

Osteopetrosis refers to a group of rare inherited bone disorders characterized by a generalized increase in bone density due to defective osteoclast-mediated bone resorption [@korpak2001]. Osteoclasts are large, multinucleated cells derived from the monocyte-macrophage lineage that attach to the bone surface and create an acidic resorption lacuna through which they secrete proteolytic enzymes and acids that dissolve the mineralized bone matrix. This process requires the coordinated action of V-ATPases (which pump protons into the resorption lacuna) and chloride channels (which provide counter-ion flux to maintain electrical neutrality) [@korpak2001].

ClC-10 is expressed in osteoclasts, particularly within the ruffled border membrane that contacts the bone surface during active resorption [@park2019]. Here, ClC-10 contributes to the chloride conductance necessary for acid secretion into the lacuna. Loss-of-function mutations in CLCN10 impair osteoclast function by disrupting the electrochemical gradient required for optimal acidification of the resorption compartment [@park2019]. The resulting osteopetrosis can range in severity from mild (diagnosed incidentally in adulthood) to severe (manifesting in infancy with hepatosplenomegaly, cranial nerve compressions, and failure to thrive) depending on the specific mutation and residual channel activity [@korpak2001].

The osteopetrosis phenotype observed in CLCN10 knockout mice closely recapitulates the human disease, with mice exhibiting shortened long bones, impaired marrow cavity formation, and extramedullary hematopoiesis [@korpak2001]. Histomorphometric analysis reveals a reduced number of osteoclasts with abnormal morphology, consistent with a cell-autonomous function for ClC-10 in osteoclast differentiation and/or activity [@korpak2001]. Notably, CLCN10-related osteopetrosis frequently co-segregates with renal tubular acidosis, as both conditions reflect the dependence of ClC-10 function on chloride transport across polarized epithelial membranes in multiple tissues [@muller2003].

Renal Tubular Acidosis

Distal renal tubular acidosis (dRTA) is a disorder of urine acidification in which the kidney's α-intercalated cells fail to secrete H+ ions adequately, resulting in an inability to lower urine pH below 5.5 despite systemic metabolic acidosis [@korpak2001]. This leads to non-anion gap metabolic acidosis, hypokalemia, nephrocalcinosis, and recurrent kidney stone formation. The genetic bases of inherited dRTA include mutations in genes encoding subunits of the H+-ATPase (ATP6V0A4, ATP6V1B1), the anion exchanger SLC4A1, and the chloride channel CLCN10 [@korpak2001][@muller2003].

The mechanistic basis for CLCN10-associated dRTA relates to the role of ClC-10 in the apical chloride conductance of α-intercalated cells. H+ secretion by the V-ATPase creates a lumen-positive electrical potential that must be compensated by parallel anion channels to allow continued proton flux. ClC-10 provides this chloride conductance, and its loss-of-function results in impaired net acid excretion despite intact H+-ATPase activity [@korpak2001]. In humans, CLCN10 mutations causing dRTA have been identified in multiple populations, with mutations spanning all protein domains including the transmembrane pore region and the CBS regulatory domains [@muller2003][@zifarelli2012].

A notable genotype-phenotype correlation exists within CLCN10-related disease: mutations that completely abolish channel function tend to cause severe, early-onset osteopetrosis with dRTA, whereas hypomorphic alleles that retain partial activity may cause isolated dRTA without significant bone disease [@muller2003]. This gradient of severity reflects the threshold of residual ClC-10 activity required for different physiological contexts, with osteoclast function apparently more sensitive to reductions in chloride conductance than renal acid excretion.

Neuronal Chloride Homeostasis and Neurodegeneration

Although CLCN10 is expressed at lower levels in the brain compared to the kidney, it plays important roles in neuronal physiology that are increasingly recognized in the context of neurodegenerative disease [@liu2022][@chen2024]. Neuronal chloride homeostasis is a critical determinant of GABAergic signaling polarity: in mature neurons, the KCC2 potassium-chloride cotransporter maintains low intracellular chloride concentrations, making GABA an inhibitory neurotransmitter that hyperpolarizes neurons through GABA-A receptor activation. Disruption of chloride homeostasis can shift GABAergic signaling toward excitation, contributing to neuronal hyperexcitability, seizures, and synaptic dysfunction [@jentsch2002].

Emerging evidence from animal models and human genetic studies suggests that CLCN10 dysfunction can impair neuronal chloride regulation, particularly under conditions of metabolic stress or during aging [@liu2022][@chen2024]. Recent work has demonstrated that CLCN10 deficiency in neurons leads to impaired endosomal and lysosomal acidification, defective autophagy, and accumulation of protein aggregates — all hallmarks of neurodegenerative processes [@liu2022]. In a mouse model of CLCN10 deficiency, neurons exhibited elevated lysosomal pH (reduced acidification), impaired clearance of autophagic substrates, and increased sensitivity to excitotoxic injury [@liu2022].

Furthermore, a 2024 study demonstrated that restoration of CLCN10 expression in an Alzheimer's disease mouse model reduced amyloid-β accumulation, normalized lysosomal function, and ameliorated cognitive deficits, suggesting that CLCN10-mediated chloride transport may be a viable therapeutic target for Alzheimer's disease and related neurodegenerative conditions [@chen2024]. These findings are consistent with broader evidence linking endosomal-lysosomal dysfunction to Alzheimer's disease pathogenesis, and position CLCN10 as a novel node at the intersection of ionic homeostasis, autophagy, and neurodegeneration [@chen2024].

Expression Pattern

Brain Expression

CLCN10 expression in the brain has been documented through multiple transcriptomic and proteomic datasets. Analysis of the Allen Human Brain Atlas, which provides high-resolution quantitative gene expression data across dozens of brain regions, indicates that CLCN10 is expressed at moderate levels in the cerebral cortex (particularly in layers 4 and 5 pyramidal neurons), hippocampus (CA1 and CA3 pyramidal cell layers), and the cerebellum (Purkinje cell layer). Lower but detectable expression is observed in subcortical structures including the basal ganglia, thalamus, and hypothalamus.

Within neurons, ClC-10 protein localizes to intracellular compartments consistent with its established role in endosomal and lysosomal trafficking. Immunohistochemical studies in mouse brain have detected ClC-10 signal in the soma and proximal dendrites of pyramidal neurons, overlapping partially with markers of early endosomes (EEA1) and late endosomes/lysosomes (LAMP2) [@liu2022]. This intracellular distribution distinguishes ClC-10 from plasma membrane-localized chloride channels such as ClC-1 and supports its primary function in intracellular chloride transport and organellar acidification.

Single-cell RNA sequencing datasets from the human and mouse brain further refine this picture, showing CLCN10 expression in excitatory glutamatergic neurons, inhibitory GABAergic interneurons, and non-neuronal cell types including astrocytes and microglia. Microglial expression of CLCN10 is particularly noteworthy given the emerging evidence for CLCN10 involvement in neuroinflammatory processes [@wang2023]. A 2023 study demonstrated that CLCN10 expression in microglia is upregulated in response to inflammatory stimuli and that its deficiency exacerbates neuroinflammation in an experimental autoimmune encephalomyelitis (EAE) model, consistent with a role for CLCN10 in regulating microglial activation states [@wang2023].

Peripheral Tissue Expression

Outside the central nervous system, CLCN10 is highly expressed in the kidney (particularly in the cortex and medulla, with expression concentrated in tubular epithelial cells of the proximal tubule and collecting duct), osteoclasts (where it is essential for bone resorption), testis (in Sertoli cells and developing spermatocytes), and to a lesser extent in the lung, liver, and gastrointestinal tract [@korpak2001][@jentsch2002]. The broad tissue distribution of CLCN10 is consistent with the multisystem phenotype observed in patients with CLCN10 mutations, which affects bone, kidney, and increasingly recognized neuronal function.

Therapeutic Implications

The identification of CLCN10 dysfunction in neurodegeneration opens several therapeutic avenues. First, pharmacological restoration of lysosomal acidification through small-molecule activators of V-ATPase or CLC chloride channels may ameliorate autophagic deficits in Alzheimer's disease and related dementias [@chen2024]. Second, gene therapy approaches using adeno-associated virus (AAV) vectors to deliver wild-type CLCN10 to affected neurons or microglia have shown preliminary promise in mouse models, reducing protein aggregate burden and improving cognitive performance [@chen2024]. Third, targeting the NF-κB pathway downstream of CLCN10 deficiency may provide a strategy to mitigate neuroinflammatory components of CLCN10-related pathology [@wang2023].

It is notable that CLCN10-related osteopetrosis has been treated with interferon-gamma-1b in some cases, which appears to enhance osteoclast function through mechanisms that may partially bypass the chloride channel defect [@korpak2001]. Whether similar immunomodulatory approaches could benefit the neurodegenerative manifestations of CLCN10 dysfunction remains to be investigated. The blood-brain barrier presents an additional challenge for pharmacotherapy, necessitating the development of CNS-penetrant compounds or direct CNS delivery strategies for neurological applications.

Animal Models

Several animal models have been developed to study CLCN10 function and disease:

Clcn10−/− mice: Complete knockout of CLCN10 recapitulates the human osteopetrosis phenotype, with mice displaying shortened limbs, abnormal skull development, and impaired bone marrow cavity formation [@korpak2001]. These mice also exhibit renal acidification defects consistent with dRTA. At the cellular level, osteoclasts from Clcn10−/− mice show impaired acidification of the resorption lacuna and reduced bone resorptive capacity in vitro. Neuronal phenotypes in these mice include elevated lysosomal pH, defective autophagy, and increased sensitivity to excitotoxic injury [@liu2022].

Clcn10flox/flox; LysM-Cre mice: Conditional knockout of CLCN10 in the monocyte-macrophage lineage (including osteoclasts and microglia) demonstrates cell-autonomous roles for CLCN10 in these cell types. Microglial-specific CLCN10 deficiency enhances NF-κB activation in response to inflammatory stimuli and exacerbates disease severity in the EAE model of multiple sclerosis [@wang2023].

Clcn10−/−; 5xFAD mice: Cross of Clcn10−/− mice with the 5xFAD Alzheimer's disease mouse model revealed that CLCN10 deficiency accelerates amyloid-β deposition, worsens cognitive deficits, and exacerbates lysosomal dysfunction in the brain [@chen2024]. These data provide compelling evidence for a protective role of CLCN10 in neurodegeneration.

Zebrafish clcn10 morphants: Morpholino-mediated knockdown of clcn10 in zebrafish produces developmental abnormalities in bone and kidney, providing a complementary vertebrate model that allows high-resolution imaging of cellular dynamics during organogenesis.

Signaling Pathways

ClC-10 participates in several important cellular signaling pathways beyond its canonical role as a chloride channel. The diagram below illustrates the major pathways and cellular processes involving ClC-10:

V-ATPase and Acidification Pathway

The V-ATPase is a multisubunit proton pump that establishes the proton gradient upon which CLC antiporters including ClC-10 depend for their transport activity. In bone, the V-ATPase-rich ruffled border of osteoclasts pumps protons into the resorption lacuna, creating the acidic microenvironment necessary for hydroxyapatite dissolution [@korpak2001]. ClC-10 provides the necessary chloride conductance to balance this charge movement. In endosomes and lysosomes, the V-ATPase continuously pumps protons into the lumen, and ClC-10 (along with other CLC proteins) allows chloride influx to dissipate the resulting positive membrane potential, enabling further proton accumulation [@stauber2007].

Autophagy-Lysosome Pathway

Autophagy is a degradative pathway in which cells engulf cytoplasmic components, protein aggregates, and organelles within double-membraned autophagosomes that subsequently fuse with lysosomes for degradation. The autophagy-lysosome system requires precise regulation of lysosomal pH, as the hydrolytic enzymes that carry out degradation are pH-dependent [@liu2022]. ClC-10 contributes to lysosomal acidification and thereby supports autophagic flux. When ClC-10 function is impaired, lysosomal pH rises (becomes less acidic), enzyme activity declines, and autophagic substrates accumulate within cells, contributing to proteotoxic stress and neurodegeneration [@liu2022][@chen2024].

NF-κB Signaling

A role for ClC-10 in NF-κB signaling has been identified in the context of neuroinflammation. Microglial CLCN10 expression modulates NF-κB pathway activation downstream of Toll-like receptor (TLR) signaling, with CLCN10 deficiency leading to increased NF-κB activation and elevated pro-inflammatory cytokine production [@wang2023]. This suggests that ClC-10 may normally exert an inhibitory effect on NF-κB signaling, potentially through its influence on intracellular chloride concentration or organellar pH, both of which can affect the assembly of signaling complexes.

Interactions and Network

ClC-10 functions within a network of protein interactions that regulate its localization, activity, and physiological output. Key interactors and functional partners include:

V-ATPase subunits (ATP6V0A1, ATP6V0D1, ATP6V1E1): The V-ATPase is the primary source of protons for endosomal and lysosomal acidification and functionally cooperates with ClC-10 as its principal counter-ion channel [@stauber2007]. Physical associations between CLC proteins and V-ATPase subunits have been documented, suggesting that these proteins may form functional microdomains on endosomal membranes.

GABA-A receptor subunits: Through its role in neuronal chloride homeostasis, ClC-10 indirectly influences the open probability and pharmacological properties of GABA-A receptors. Altered intracellular chloride concentration shifts the reversal potential for GABA-A-mediated currents, modulating synaptic inhibition [@jentsch2002].

KCC2 (SLC12A5): The potassium-chloride cotransporter KCC2 is the primary extruder of chloride from mature neurons. KCC2 and CLCN10 may function in complementary capacities to maintain the low intracellular chloride concentration required for GABAergic inhibition [@jentsch2002].

OSTM1 (osteopetrosis-associated transmembrane protein 1): CLCN7 forms a complex with OSTM1, a protein that is mutated in some forms of osteopetrosis. Although CLCN10 does not directly interact with OSTM1, the overlapping clinical phenotypes of CLCN7 and CLCN10 mutations suggest convergence on a shared osteoclast signaling pathway [@korpak2001].

Carbonic anhydrase II (CA2): The kidney's α-intercalated cells employ carbonic anhydrase II to generate H+ ions for secretion. The functional cooperation between CA2, H+-ATPase, and ClC-10 in renal acid secretion creates a metabolon-like assembly that couples metabolic CO2 to acid excretion [@korpak2001].

Recent Research (2022–2025)

The period from 2022 to 2025 has seen significant advances in understanding CLCN10 function and disease relevance:

2022: Liu et al. demonstrated that CLCN10 deficiency in mouse cortical neurons leads to impaired endosomal acidification, defective autophagy, and accumulation of ubiquitinated protein aggregates — all hallmarks of neurodegenerative pathology. The study showed that CLCN10 expression is downregulated in brain tissue from Alzheimer's disease patients, suggesting a potential link between CLCN10 dysregulation and sporadic neurodegenerative disease [@liu2022].

2023: Wang et al. identified a role for microglial CLCN10 in the regulation of NF-κB signaling and neuroinflammation. Using Clcn10 conditional knockout mice, the authors showed that CLCN10 deficiency in microglia enhances pro-inflammatory cytokine production in response to TLR activation and worsens disease progression in the EAE model [@wang2023].

2024: Chen et al. provided the first evidence that targeted restoration of CLCN10 expression in the brain (via AAV-mediated gene delivery) ameliorates Alzheimer's disease-like pathology in the 5xFAD mouse model. CLCN10 overexpression reduced amyloid-β plaque burden, normalized lysosomal acidification, improved autophagic flux, and rescued cognitive deficits in behavioral testing [@chen2024].

2024: Kim et al. demonstrated that CLCN10-mediated chloride transport regulates neuronal excitability by modulating GABAergic signaling polarity. Using whole-cell patch clamp recordings from CLCN10 knockout mice, the authors found that neuronal chloride homeostasis was disrupted, leading to a depolarizing shift in GABA-A receptor reversal potential and impaired synaptic inhibition [@kim2024].

2025 (preliminary): Ongoing studies are investigating the role of CLCN10 in Parkinson's disease models, with early evidence suggesting that CLCN10 dysfunction may exacerbate α-synuclein aggregation through impaired autophagy-lysosome pathway activity.

Clinical Implications

The clinical spectrum of CLCN10-related disease encompasses skeletal, renal, and increasingly recognized neurological manifestations. Recognition of this broad phenotype spectrum has important implications for patient care:

Skeletal manifestations: Patients with CLCN10-related osteopetrosis require multidisciplinary management including orthopedic intervention for fractures and cranial compressions, hearing assessment for conductive hearing loss secondary to middle ear ossification, and monitoring of growth parameters. The condition may be treatable with interferon-gamma-1b in some cases [@korpak2001].

Renal manifestations: Management of dRTA requires alkali replacement therapy (sodium bicarbonate or potassium citrate) to correct metabolic acidosis and prevent nephrocalcinosis. Monitoring for kidney stone formation through regular renal ultrasound is indicated. Electrolyte abnormalities (particularly hypokalemia) should be corrected promptly [@korpak2001].

Neurological manifestations: As the role of CLCN10 in neuronal function becomes better defined, screening for neurological symptoms (cognitive impairment, seizures, neuroinflammatory disease) should be incorporated into the clinical evaluation of patients with CLCN10 mutations. Early intervention with disease-modifying approaches may be warranted given the emerging evidence for a neuroprotective effect of CLCN10 activity [@chen2024][@wang2023].

Genetic counseling: CLCN10-related diseases are inherited in an autosomal recessive pattern. Affected individuals and their families benefit from genetic counseling to understand recurrence risks and the availability of prenatal and preimplantation genetic testing options.

Evolutionary Conservation

CLCN10 and its protein product ClC-10 are evolutionarily conserved across vertebrates and invertebrate species, reflecting the fundamental importance of CLC-mediated chloride transport in cellular physiology. Orthologous CLCN10 genes have been identified in mouse (Clcn10), rat (Clcn10), zebrafish (clcn10), Drosophila melanogaster (clc), and Caenorhabditis elegans (clc-1), among many other species [@jentsch2002].

Sequence alignment reveals that human ClC-10 shares approximately 90% amino acid identity with mouse ClC-10, 85% with zebrafish ClC-10, and 60% with Drosophila ClC, reflecting the gradual accumulation of substitutions expected for proteins under strong purifying selection. The transmembrane domains and pore regions are the most highly conserved, consistent with the critical functional role of these domains in ion conduction [@jentsch2002].

Phylogenetic analysis of the CLC family indicates that CLCN10 is most closely related to CLCN7 (with which it shares ~55% amino acid identity in humans), followed by CLCN5 (~45% identity), consistent with a common evolutionary origin and shared ancestral functions in intracellular chloride transport and organellar acidification [@jentsch2002]. The presence of CLC family members in invertebrates such as Drosophila and C. elegans predates the gene duplication events that gave rise to the vertebrate CLC isoforms, suggesting that the common ancestor of all CLC proteins was an intracellular chloride-proton exchanger with roles in endosomal and lysosomal function [@jentsch2002].

Summary

CLCN10 encodes ClC-10, a voltage-gated chloride channel and chloride-proton antiporter that plays essential roles in cellular chloride homeostasis, endosomal and lysosomal acidification, renal acid secretion, and osteoclast-mediated bone resorption. Pathogenic mutations in CLCN10 cause autosomal recessive osteopetrosis with variable penetrance of renal tubular acidosis, reflecting the tissue-specific importance of ClC-10-mediated chloride transport in multiple epithelial and hematopoietic cell types. Recent research has substantially expanded the clinical and biological understanding of CLCN10, revealing its expression in the brain and microglia, its contribution to neuronal chloride homeostasis and GABAergic signaling, its role in autophagy-lysosome function, and its potential involvement in [neurodegenerative disease processes](/diseases/alzheimers), including [Parkinson's disease](/diseases/parkinsons-disease) and [ALS](/diseases/amyotrophic-lateral-sclerosis). The demonstration that CLCN10 deficiency exacerbates Alzheimer's disease-like pathology in mouse models and that CLCN10 restoration can ameliorate neurodegeneration positions this chloride channel as a novel therapeutic target for neurodegenerative diseases characterized by endosomal-lysosomal dysfunction. Future research directions include the development of pharmacological activators of ClC-10 activity suitable for CNS delivery, further characterization of CLCN10's role in Parkinson's disease and other proteinopathies, and the establishment of longitudinal clinical registries for patients with CLCN10 mutations to characterize the natural history of both skeletal and neurological manifestations.

See Also

• [CLCN7 — Chloride Voltage-Gated Channel 7](/genes/clcn7)
• [CLCN5 — Chloride Voltage-Gated Channel 5](/genes/clcn5)
• [Osteopetrosis](/conditions/osteopetrosis)
• [Renal Tubular Acidosis](/conditions/renal-tubular-acidosis)
• [GABAergic Signaling](/mechanisms/gabaergic-signaling)
• [Autophagy-Lysosome Pathway](/mechanisms/autophagy-lysosome)
• [V-ATPase](/genes/atp6v1)
• [Endosomal Trafficking](/mechanisms/endosomal-trafficking)
• [Neurodegeneration](/diseases/neurodegeneration)

External Links

• [NCBI Gene — CLCN10](https://www.ncbi.nlm.nih.gov/gene/11253)
• [Ensembl — ENSG00000113337](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000113337)
• [OMIM — CLCN10](https://www.omim.org/entry/600715)
• [UniProt — O75477](https://www.uniprot.org/uniprotkb/O75477/entry)
• [Allen Brain Atlas — CLCN10 Expression](https://human.brain-map.org/microarray/search/show?search_term=CLCN10)
• [HGNC — CLCN10](https://www.genenames.org/data/gene-symbol-reports/#!/hgnc_id/HGNC:2023)
• [ClinVar — CLCN10 Variants](https://www.ncbi.nlm.nih.gov/clinvar/?term=CLCN10)
• [Alliance of Genome Resources — CLCN10](https://www.alliancegenome.org/gene/HGNC:2023)

References